Matthew Ros
Director/Board Member chez COGENT BIOSCIENCES, INC.
Fortune : - $ au 31/03/2024
Profil
Matthew E.
Ros is an Independent Director at Cogent Biosciences, Inc. He previously served as the Chief Executive Officer & Director at Fore Biotherapeutics, Inc. from 2022 to 2023.
Prior to that, he held the position of Senior Director at Bristol Myers Squibb Co. from 1990 to 2007.
From 2007 to 2010, he worked as the Senior Vice President-Commercial Operations at ARIAD Pharmaceuticals, Inc. He also served as the Vice President & Head-Franchise at Genzyme Corp.
from 2012 to 2014 and as the Associate Vice President at Sanofi from 2010 to 2012.
From 2014 to 2016, he held the role of COO, VP & Global Head-Oncology Business Unit at Sanofi.
Additionally, he served as a Trustee at Cancer Care, Inc. Mr. Ros's education includes an undergraduate degree from The State University of New York, which he obtained in 1988.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
COGENT BIOSCIENCES, INC.
-.--% | 22/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Matthew Ros
| Sociétés | Poste | Début |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Director/Board Member | 26/07/2019 |
Anciens postes connus de Matthew Ros
| Sociétés | Poste | Fin |
|---|---|---|
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Chief Executive Officer | 01/08/2023 |
| EPIZYME, INC. | Director of Finance/CFO | 01/10/2021 |
| SANOFI | Chief Operating Officer | 01/05/2016 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/12/2014 |
| SANOFI | Corporate Officer/Principal | 01/09/2012 |
Formation de Matthew Ros
| The State University of New York | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| SANOFI | Health Technology |
| COGENT BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Cancer Care, Inc. provides cancer treatment services. The firm's services include counseling and support groups, education, financial assistance and practical help. The company was founded in 1944 and is headquartered in New York, NY. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
